Otonomy, Inc.

154 articles with Otonomy, Inc.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

  6/15/2021

  Otonomy, Inc. today announced the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.

• Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

  5/14/2021

  OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency

• Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/11/2021

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter ended March 31, 2021 and provided an update on its product pipeline and corporate activities.

• Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

  5/4/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on May 11, 2021.

• Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

  4/28/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 13, 2021.

• Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Apr 19, 2021

  4/19/2021

  Otonomy, Inc. announced the closing of its previously announced underwritten public offering of 8,298,890 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and pre-funded warrants to purchase up to 7,111,110 shares of its common stock for total gross proceeds of approximately $34.7 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Otonomy.

• 

  Clinical Catch-Up: April 5-9

  4/12/2021

  It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.

• Otonomy Announces Pricing of $30.1 Million Public Offering

  4/8/2021

  Otonomy, Inc. announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to the public of $2.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,111,110 shares of its common stock at a purchase price of $2.249 per each pre-funded warrant

• Otonomy Announces Proposed Public Offering

  4/7/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock.

• Otonomy to Present at the Needham Virtual Healthcare Conference

  4/6/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the 20 th Annual Needham Virtual Healthcare Conference. David A. Weber, Ph.D., president and CEO of Otonomy, will present a company overview on Tuesday, April 13, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

• Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting

  4/5/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at the upcoming American Neurotology Society’s 56 th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021.

• Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

  3/25/2021

  Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpoint Patient enrollment criteria refined to enrich study population Top-line results expected in mid-2022

• Otonomy to Participate in Three Upcoming Investor Conferences

  2/25/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences: A fireside chat at the Cowen 41st Annual Health Care Conference on March 4, 2021 at 12:50 p.m. ET / 9:50 a.m. PT;

• 

  Otonomy Shifts Focus to Hearing Loss and Tinnitus After Meniere's Phase III Failure

  2/22/2021

  Otonomy shares plunged 50.1% at news that its drug to treat Meniere’s disease failed to hit the primary endpoint in its Phase III trial.

• Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

  2/22/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for OTIVIDEX vs. placebo

• Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

  2/17/2021

  Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program

• Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  2/11/2021

  OTIVIDEX ® Phase 3 trial results in Ménière’s disease expected by end of February OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 Conference call and webcast today at 4:30 p.m. ET

• Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

  2/4/2021

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

• Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference

  1/5/2021

  Otonomy, Inc. announced that management is scheduled to participate in a fireside chat at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.